Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

700 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
Moodie Z, Andersen-Nissen E, Grunenberg N, Dintwe OB, Omar FL, Kee JJ, Bekker LG, Laher F, Naicker N, Jani I, Mgodi NM, Hunidzarira P, Sebe M, Miner MD, Polakowski L, Ramirez S, Nebergall M, Takuva S, Sikhosana L, Heptinstall J, Seaton KE, De Rosa S, Diazgranados CA, Koutsoukos M, Van Der Meeren O, Barnett SW, Kanesa-Thasan N, Kublin JG, Tomaras GD, McElrath MJ, Corey L, Mngadi K, Goepfert P; HVTN 107 Protocol Team. Moodie Z, et al. Among authors: bekker lg. PLoS Med. 2024 Mar 19;21(3):e1004360. doi: 10.1371/journal.pmed.1004360. eCollection 2024 Mar. PLoS Med. 2024. PMID: 38502656 Free PMC article. Clinical Trial.
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.
Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG; HVTN 503/Phambili study team. Gray GE, et al. Among authors: bekker lg. Lancet Infect Dis. 2011 Jul;11(7):507-15. doi: 10.1016/S1473-3099(11)70098-6. Epub 2011 May 11. Lancet Infect Dis. 2011. PMID: 21570355 Free PMC article. Clinical Trial.
Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.
Chihana R, Jin Kee J, Moodie Z, Huang Y, Janes H, Dadabhai S, Roxby AC, Allen M, Kassim S, Naicker V, Innes C, Naicker N, Dubula T, Grunenberg N, Malahleha M, Kublin JG, Bekker LG, Gray G, Kumwenda J, Laher F. Chihana R, et al. Among authors: bekker lg. Vaccine. 2024 May 21:S0264-410X(24)00598-X. doi: 10.1016/j.vaccine.2024.05.039. Online ahead of print. Vaccine. 2024. PMID: 38772835
High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron.
Garrett N, Tapley A, Andriesen J, Seocharan I, Fisher LH, Bunts L, Espy N, Wallis CL, Randhawa AK, Ketter N, Yacovone M, Goga A, Bekker LG, Gray GE, Corey L. Garrett N, et al. Among authors: bekker lg. medRxiv [Preprint]. 2022 Jan 14:2021.12.20.21268130. doi: 10.1101/2021.12.20.21268130. medRxiv. 2022. PMID: 35043118 Free PMC article. Preprint.
Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
Takalani A, Robinson M, Jonas P, Bodenstein A, Sambo V, Jacobson B, Louw V, Opie J, Peter J, Rowji P, Seocharan I, Reddy T, Yende-Zuma N, Khutho K, Sanne I, Bekker LG, Gray G, Garrett N, Goga A; Sisonke Study Team. Takalani A, et al. Among authors: bekker lg. Vaccine. 2024 Feb 27;42(6):1195-1199. doi: 10.1016/j.vaccine.2024.01.066. Epub 2024 Jan 25. Vaccine. 2024. PMID: 38278629 Clinical Trial.
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
Moyo-Gwete T, Richardson SI, Keeton R, Hermanus T, Spencer H, Manamela NP, Ayres F, Makhado Z, Motlou T, Tincho MB, Benede N, Ngomti A, Baguma R, Chauke MV, Mennen M, Adriaanse M, Skelem S, Goga A, Garrett N, Bekker LG, Gray G, Ntusi NAB, Riou C, Burgers WA, Moore PL. Moyo-Gwete T, et al. Among authors: bekker lg. medRxiv [Preprint]. 2023 Mar 15:2023.03.15.23287288. doi: 10.1101/2023.03.15.23287288. medRxiv. 2023. PMID: 36993404 Free PMC article. Updated. Preprint.
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
Moyo-Gwete T, Richardson SI, Keeton R, Hermanus T, Spencer H, Manamela NP, Ayres F, Makhado Z, Motlou T, Tincho MB, Benede N, Ngomti A, Baguma R, Chauke MV, Mennen M, Adriaanse M, Skelem S, Goga A, Garrett N, Bekker LG, Gray G, Ntusi NAB, Riou C, Burgers WA, Moore PL. Moyo-Gwete T, et al. Among authors: bekker lg. PLoS Pathog. 2023 Nov 9;19(11):e1011772. doi: 10.1371/journal.ppat.1011772. eCollection 2023 Nov. PLoS Pathog. 2023. PMID: 37943890 Free PMC article.
Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety.
Restrepo J, Herrera T, Samakoses R, Reina JC, Pitisuttithum P, Ulied A, Bekker LG, Moreira ED, Olsson SE, Block SL, Hammes LS, Laginha F, Ferenczy A, Kurman R, Ronnett BM, Stoler M, Bautista O, Gallagher NE, Salituro G, Ye M, Luxembourg A. Restrepo J, et al. Among authors: bekker lg. Pediatrics. 2023 Oct 1;152(4):e2022060993. doi: 10.1542/peds.2022-060993. Pediatrics. 2023. PMID: 37667847
Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.
Bhiman JN, Richardson SI, Lambson BE, Kgagudi P, Mzindle N, Kaldine H, Crowther C, Gray G, Bekker LG; Novavax trial clinical lead author group; Shinde V, Bennett C, Glenn GM, Madhi SA, Moore PL. Bhiman JN, et al. Among authors: bekker lg. Sci Rep. 2023 Jan 21;13(1):1222. doi: 10.1038/s41598-023-27698-x. Sci Rep. 2023. PMID: 36681693 Free PMC article.
700 results